[1] Florio A A, Ferlay J, Znaor A, et al. Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012[J]. Cancer,2020,126:2666-2678.
[2] Zhang X F, Beal E W, Bagante F,et al. Early versus late recurrence of intrahepatic cholangio-carcinoma after resection with curative intent[J]. Br J Surg, 2018, 105:848-856.
[3] Koerkamp B G, Wiggers J K, Allen P J, et al. Recurrence rate and pattern of perihilar cholangiocarcinoma after curative intent resection[J]. J Am Coll Surg,2015,221:1041-1049.
[4] McMasters K M, Tuttle T M, Leach S D,et al. Neoadjuvant chemoradiation for extrahepaticchol-angiocarcinoma[J]. Am J Surg,1997,174:605-608, discussion608-609.
[5] Mason M C,Massarweh N N,Tzeng C W D,et al. Time to rethink upfront surgery for resectable intrahepatic cholangiocarcinoma? Implications from the neoadjuvant experience[J]. Ann Surg Oncol,2021,28:6725-6735.
[6] Le Roy B, Gelli M, Pittau G,et al. Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma[J]. Br J Surg, 2018,105:839-847.
[7] Jung J H,Lee H J,Lee H S,et al. Benefit of neoadjuvant concurrent chemoradiotherapy for locally advanced perihilar cholangiocarcinoma[J]. World J Gastroenterol,2017,23:3301-3308
[8] Rayar M, Sulpice L, Edeline J, et al. Intra-arterial yttrium-90 radioembolization combined with systemic chemotherapy is a promising method for downstaging unresectable huge intrahepatic cholangiocarcinoma to surgical treatment[J]. Ann Surg Oncol,2015,22:31028.
[9] Sumiyoshi T, Shima Y, Okabayashi T, et al. Chemoradiotherapy for initially unresectable locally advanced cholangiocarcinoma. World J Surg[J]. 2018, 42: 2910-2918.
[10] Riby D,Mazzotta A D, Bergeat D,et al. Downstaging with radioembolization or chemotherapy for initially unresectable intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol,2020,27:3729-3737.
[11] Maithel S K, Keilson J M, Cao H S T,et al. NEO-GAP: a single-arm, phase Ⅱ feasibility trial of neoadjuvant gemcitabine, cisplatin, and nab-paclitaxel for resectable, high-risk intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol,2023,30:6558-6566.
[12] Shroff R T, King G, Colby S, et al. SWOG S1815: a phase Ⅲ randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers[J]. J Clin Oncol,2025, 43:536-544.
[13] Katayose Y, Rikiyama T, Motoi F,Yamamoto K,Yoshida H, Morikawa T, et al. Phase Ⅰ trial of neoadjuvant chemoradiation with gemcitabine and surgical resection for cholangiocarcinoma patients (NACRAC study)[J]. Hepatogastroenterology, 2011,58: 1866-1872.
[14] De Vreede I, Steers J L, Burch P A, et al. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma[J]. Liver Transpl, 2000,6(3):309-316.
[15] Rea D J, Heimbach J K, Rosen C B,et al. Liver transplantation with neoadjuvantchemoradiation is more effective than resection for hilarcholangiocarcinoma[J]. Ann Surg,2005,242:451-458, discussion458-461.
[16] Rosen C B, Murad S D, Heimbach J K,et al. Neoadjuvant therapy and liver transplantation forhilar cholangiocarcinoma: is pretreatment pathologicalconfirmation of diagnosis necessary?[J]. J Am Coll Surg, 2012,215:31-38.
[17] Lunsford K E, Javle M, Heyne K, et al. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series[J]. Lancet Gastroenterol Hepatol, 2018,3:337-348.
[18] Goetze T O, Bechstein W O, Bankstahl U S, et al. Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC)-a phase Ⅲ study of the German registry of incidental gallbladder carcinoma platform (GR)-the AIO/CALGP/ACO-GAIN-trial[J]. BMC Cancer, 2020,20(1):122.
[19] Goetze T O, Vogel A, Pratschke J,et al. Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone followed adjuvant therapy in biliary tract cancer: Final results from the phase Ⅲ AIO/CALGP/ACO-GAIN-Trial[J]. J Clin Oncol,2025,43:4008.
[20] Merath K, Tiwari A, Parikh A A, et al. Molecular targeted and systemic therapy for intrahepatic cholangiocarcinoma: a multi-disciplinary approach[J]. Future Oncol,2023,19:2607-2621.
[21] Ebata T, Hirano S, Konishi M,et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer[J]. Br J Surg,2018,105:192-202.
[22] Edeline J, Benabdelghani M, Bertaut A,et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12ACCORD 18-UNICANCER GI): a randomized phase Ⅲ study[J]. J Clin Oncol,2019,37:658-667.
[23] Bridgewater J, Fletcher P, Palmer D H, et al. Long-term outcomes and exploratory analyses of the randomized phase Ⅲ BILCAP study[J]. J Clin Oncol,2022,40(18):2048-2057.
[24] Nakachi K, Ikeda M, Konishi M, et al. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial[J]. Lancet,2023,401(10372):195-203.
[25] Ben-Josef E, Guthrie K A, El-Khoueiry A B,et al. SWOG S0809:a phase Ⅱ intergroup trial of adjuvant capecitabine and gemcitabine followed by radio-therapy and concurrent capecitabine in extrahepatic cholangio-carcinoma and gallbladder carcinoma[J]. J Clin Oncol, 2015,33: 2617-2622.
[26] Ghidini M, Tomasello G, Botticelli A,et al. Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis[J]. HPB,2017,19:741-748.
[27] Stein A, Arnold D, Bridgewater J, et al. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial)-a randomized, multidisciplinary, multinational phase Ⅲ trial[J]. BMC Cancer,2015,15:564. |
